Despite the worldwide prevalence of rare bleeding disorders (RBDs), knowledge of these
conditions and their management is suboptimal; health care professionals often have little …

The formation of fibrin clots that are relatively resistant to lysis represents the final step in
blood coagulation. We discuss the genetic and environmental regulators of fibrin structure in …

Background: The European Network of Rare Bleeding Disorders (EN‐RBD) was established
to bridge the gap between knowledge and practise in the care of patients with RBDs …

Factor XIII (FXIII) is unique among clotting factors for a number of reasons: 1) it is a
protransglutaminase, which becomes activated in the last stage of coagulation; 2) it works …

Venous thrombi, fibrin-and rbc-rich clots triggered by inflammation and blood stasis, underlie
devastating, and sometimes fatal, occlusive events. During intravascular fibrin deposition …

Factor XIII (FXIII) is a transglutaminase enzyme that catalyses the formation of ε-(γ-glutamyl)
lysyl isopeptide bonds into protein substrates. The plasma form, FXIIIA2B2, has an …

Diagnosis and classification of factor XIII deficiencies - ScienceDirect Skip to main contentSkip
to article Elsevier logo Journals & Books Search RegisterSign in View PDF Download full issue …

As the third most common vascular disease, venous thromboembolism is associated with
significant mortality and morbidity. Pathogenesis underlying venous thrombosis is still not …

Publications known to the writing group were supplemented with additional papers identified
by searching Medline/PubMed for publications in the last 12 years using keywords …

Factor (F) XIII is a protransglutaminase that, in addition to maintaining hemostasis, has
multiple plasmatic and intracellular functions. Its plasmatic form (pFXIII) is a tetramer of two …